Pimobendan 74150-27-9 Metabolism PDE inhibitor
Tefo:T/T, L/C
Tšimoloho ea Sehlahisoa:China
Boema-kepe:Beijing/Shanghai/Hangzhou
Odara (MOQ):1g
Lead time:3 matsatsi a ho sebetsa
Bokhoni ba tlhahiso:1kg/khoeli
Boemo ba polokelo:E bolokiloe sebakeng se pholileng, se omileng, mocheso oa kamore.
Lintho tsa sephutheloana:vial, botlolo
Boholo ba sephutheloana:1g/vial, 5/vial, 10g/vial, 50g/botlolo, 500g/botlolo
Lintlha tsa polokeho:UN 2811 6.1/PG 3
Selelekela
Pimobendan, ke moriana oa bongaka ba liphoofolo.Ke calcium sensitizer le inhibitor e khethiloeng ea phosphodiesterase 3 (PDE3) e nang le liphello tse ntle tsa inotropic le vasodilator.
Pimobendan e sebelisoa ho laola ho hloleha ha pelo ho lintja, hangata ho bakoang ke myxomatous mitral valve disease (eo pele e neng e tsejoa e le endocardiosis), kapa dilated cardiomyopathy.Patlisiso e bonts'itse hore joalo ka monotherapy, pimobendan e eketsa nako ea ho pholoha le ho ntlafatsa boleng ba bophelo ho bakuli ba canine ba nang le ho hloleha ha pelo ho latela lefu la mitral valve ha le bapisoa le benazepril, e leng ACE inhibitor.
Tlhaloso (USP43)
| Ntho | Tlhaloso |
| Ponahalo | Phofo e tšoeu kapa e mosehla hanyenyane, hygroscopic |
| Mp | Hoo e ka bang 242 ℃ |
| Solubility | Ha e khone ho qhibiliha ka metsing, e qhibiliha ka bolokolohi ho dimethylformamide, e qhibiliha hanyenyane ho acetone le methanil. |
| Boitsebiso | Infrared absorption spectrophotometry, Papiso ea pimobendan CRS. |
| Nako ea ho boloka tlhōrō e kholo ea tharollo ea Sample e lumellana le ea Standard stock solution, joalokaha e fumanoe tekong ea Organic Impurities. | |
| Litšepe tse boima | ≤10ppm |
| Granularity | P90 ≤ 25μ m |
| Boholo ba likaroloana | 20-80 mesh |
| Li-solvents tse setseng | ≤ 500ppm |
| Metsi | ≤ 1.0% |
| Tlhahlobo | 98.0%~102.0% |
| Molora o nang le sulphated | ≤ 0.10% |
| Lintho tse amanang le tsona (HPLC) | |
| litšila A | ≤ 0.10% |
| litšila B | ≤ 0.10% |
| Tšilafalo efe kapa efe | ≤ 0.10% |
| Ho se hloeke ho feletseng | ≤ 0.20% |
